IL92167A - Preparation containing activin and / or inhibin - Google Patents

Preparation containing activin and / or inhibin

Info

Publication number
IL92167A
IL92167A IL9216789A IL9216789A IL92167A IL 92167 A IL92167 A IL 92167A IL 9216789 A IL9216789 A IL 9216789A IL 9216789 A IL9216789 A IL 9216789A IL 92167 A IL92167 A IL 92167A
Authority
IL
Israel
Prior art keywords
inhibin
chain
activin
globin
composition according
Prior art date
Application number
IL9216789A
Other languages
English (en)
Hebrew (he)
Other versions
IL92167A0 (en
Original Assignee
Perrine Susan P
Albers Norbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perrine Susan P, Albers Norbert filed Critical Perrine Susan P
Publication of IL92167A0 publication Critical patent/IL92167A0/xx
Publication of IL92167A publication Critical patent/IL92167A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL9216789A 1988-11-01 1989-10-31 Preparation containing activin and / or inhibin IL92167A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/266,421 US4997815A (en) 1988-11-01 1988-11-01 Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

Publications (2)

Publication Number Publication Date
IL92167A0 IL92167A0 (en) 1990-07-12
IL92167A true IL92167A (en) 1994-07-31

Family

ID=23014518

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9216789A IL92167A (en) 1988-11-01 1989-10-31 Preparation containing activin and / or inhibin

Country Status (9)

Country Link
US (1) US4997815A (fr)
EP (2) EP0367590B1 (fr)
JP (1) JPH02256622A (fr)
AT (1) ATE119396T1 (fr)
CA (1) CA2001897A1 (fr)
DE (1) DE68921546T2 (fr)
IL (1) IL92167A (fr)
MA (1) MA21667A1 (fr)
PT (1) PT92174B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173805A (ja) * 1989-09-11 1991-07-29 Ajinomoto Co Inc 卵分割促進剤
US5166190A (en) * 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
US5102868A (en) * 1990-01-08 1992-04-07 Genentech, Inc. Method for inhibiting follicular maturation
AU7321891A (en) * 1990-02-15 1991-09-03 Cetus Corporation Inhibitor of cytokine activity and applications thereof
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
AU8761391A (en) * 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
AU7668894A (en) * 1993-08-13 1995-03-14 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US5487895A (en) * 1993-08-13 1996-01-30 Vitaphore Corporation Method for forming controlled release polymeric substrate
EP0731712A4 (fr) * 1993-10-29 2005-11-09 Univ Boston Compositions physiologiquement stables d'acide butyrique, de sels et de derives d'acide butyrique, utilisees comme agents antineoplasiques
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
EP1886677A1 (fr) 1996-07-26 2008-02-13 Susan P. Perrine Composition comprenant un agent d'induction et agent antiviral pour le traitement de maladies sanguines, virales et cellulaires
AUPO638897A0 (en) * 1997-04-23 1997-05-22 Monash University Modulation of cell growth and methods relating thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
CA2324426A1 (fr) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions et techniques de traitement de la mucoviscidose
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
JP2006513727A (ja) * 2002-05-17 2006-04-27 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー 中胚葉および成体型内胚葉細胞集団
AU2012203441B2 (en) * 2002-05-17 2015-01-29 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (fr) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Derives de n-hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide et composes associes en tant qu'inhibiteurs d'histone deacetylase pour le traitement du cancer
WO2005066151A2 (fr) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
CA2575370A1 (fr) * 2004-08-10 2006-02-23 Voyager Pharmaceutical Corporation Procedes de traitement des nourrissons prematures
EP1824831A2 (fr) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
WO2006122319A2 (fr) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
US7732475B2 (en) * 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2010105112A1 (fr) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Détection d'acides gras à chaîne courte dans des échantillons biologiques
WO2011038224A1 (fr) 2009-09-24 2011-03-31 Trustees Of Boston University Procédés pour le traitement de troubles viraux
WO2011072086A1 (fr) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Procédés et régimes à faible dose pour traiter des troubles des globules rouges
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
WO2013119800A1 (fr) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Utilisation d'antagonistes de ghréline ou de récepteur de ghréline pour prévenir ou traiter une maladie psychiatrique sensible au stress
WO2014144231A1 (fr) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Utilisation d'antagonistes de l'hormone de croissance ou de recepteur de l'hormone de croissance pour empecher ou traiter une maladie psychiatrique sensible au stress
US20160106821A1 (en) * 2014-10-20 2016-04-21 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
SG11202113215UA (en) 2019-05-31 2021-12-30 Viracta Subsidiary Inc Methods of treating virally associated cancers with histone deacetylase inhibitors
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730114B2 (ja) * 1985-04-03 1995-04-05 正雄 五十嵐 インヒビン
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
EP0299050B1 (fr) * 1987-01-29 1995-03-22 Biotechnology Australia Pty. Ltd. Isolement a partir de fluide folliculaire de proteines a chaine unique avec activite de suppression de la fsh
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis

Also Published As

Publication number Publication date
DE68921546T2 (de) 1995-07-06
EP0367590A2 (fr) 1990-05-09
CA2001897A1 (fr) 1990-05-01
US4997815A (en) 1991-03-05
PT92174A (pt) 1990-05-31
ATE119396T1 (de) 1995-03-15
EP0617966A1 (fr) 1994-10-05
IL92167A0 (en) 1990-07-12
EP0367590B1 (fr) 1995-03-08
JPH02256622A (ja) 1990-10-17
MA21667A1 (fr) 1990-07-01
DE68921546D1 (de) 1995-04-13
PT92174B (pt) 1995-09-12
EP0367590A3 (fr) 1992-01-02

Similar Documents

Publication Publication Date Title
US4997815A (en) Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
US5216004A (en) Method for preventing malaria
EP0548276A4 (en) Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5646113A (en) Treatment of partial growth hormone insensitivity syndrome
US5126324A (en) Method of enhancing growth in patients using combination therapy
AU655059B2 (en) Method of stimulating immune response
US4699897A (en) Biologically active peptides structurally related to regions within growth hormones
US20090088380A1 (en) Ghrh analogs and therapeutic uses thereof
CA2185998C (fr) Combinaison d'hormone de croissance et de facteur de croissance de type insuline dans le traitement de l'insuffisance cardiaque
AU2003229222B2 (en) GRF analog compositions and their use
US5824642A (en) Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) Treatment of partial growth hormone insensitivity syndrome
Fatouros et al. Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre-and postoperatively with erythropoietin or granulocyte macrophage–colony stimulating factor: Evidence of a previously unknown anabolic effect of erythropoietin?
JPH08502969A (ja) 肥満の予防または治療方法
US20210008164A1 (en) Erythropoietin for Gastrointestinal Dysfunction
Cotes Erythropoietin: the developing story
US5317012A (en) Human growth hormone induced improvement in depressed T4/T8 ratio
WO1999049894A1 (fr) Antagonistes du gene 6 specifique de l'arret de croissance, et leur utilisation contre des troubles insulinoresistants
Baumann Molecular heterogeneity of circulating growth hormone in acromegaly
MXPA98009140A (en) Treatment of the partial insensitivity syndrome to the growth hormone
MXPA96004802A (en) Treatment of cardiac failure congest

Legal Events

Date Code Title Description
RH Patent void